Neurogenetic Pharmaceuticals, Inc.

San Diego, CA 92121

SBIR Award Summary

Total Number of Awards 5
Total Value of Awards $3.36MM
First Award Date 07/15/11
Most Recent Award Date 12/01/13

Key Personnel

Last Name Name Awards Contact
Comer William T Comer 5

5 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-08-235
Budget: 12/01/13 - 11/30/14

DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is the most common form of senile dementia. An estimated 5.3 million Americans are affected, and this number is increasing yearly. Currently, there is no cure for AD;however, it is widely accepted that inhibiting amyloid plaque formation would be beneficial for the prevention of Alzhe...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-08-235
Budget: 12/01/13 - 11/30/14

DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is the most common form of senile dementia. An estimated 5.3 million Americans are affected, and this number is increasing yearly. Currently, there is no cure for AD;however, it is widely accepted that inhibiting amyloid plaque formation would be beneficial for the prevention of Alzhe...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-08-235
Budget: 12/01/12 - 11/30/13

DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is the most common form of senile dementia. An estimated 5.3 million Americans are affected, and this number is increasing yearly. Currently, there is no cure for AD;however, it is widely accepted that inhibiting amyloid plaque formation would be beneficial for the prevention of Alzhe...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-08-235
Budget: 04/01/12 - 11/30/12

DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is the most common form of senile dementia. An estimated 5.3 million Americans are affected, and this number is increasing yearly. Currently, there is no cure for AD;however, it is widely accepted that inhibiting amyloid plaque formation would be beneficial for the prevention of Alzhe...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-08-235
Budget: 07/15/11 - 03/31/12

DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is the most common form of senile dementia. An estimated 5.3 million Americans are affected, and this number is increasing yearly. Currently, there is no cure for AD;however, it is widely accepted that inhibiting amyloid plaque formation would be beneficial for the prevention of Alzhe...